<DOC>
	<DOCNO>NCT01246453</DOCNO>
	<brief_summary>1 . Objectives : - Main objective : To evaluate efficacy safety intrapleural alteplase vs urokinase patient complex complicate parapneumonic pleural effusion empyema . - To evaluate pleural plasmatic level fibrinolytic system marker treatment alteplase v urokinase - To evaluate safety alteplase treatment complex complicate parapneumonic pleural effusion empyema 2 . Design : Multicentric , randomize , parallel , control double blind 3 . Main variable : Percentage curation 4 . Study population number patient : 204 patient complex complicate parapneumonic pleural effusion empyema 5 . Duration treatment : Three day ( main variable ) , optional three day ( secondary variable )</brief_summary>
	<brief_title>Efficacy Security Intrapleurally Alteplase vs Urokinase Treatment Complicated Parapneumonic Effusion Empyema</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Empyema</mesh_term>
	<mesh_term>Pleural Diseases</mesh_term>
	<mesh_term>Empyema , Pleural</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Empyema Complex Complicated Parapneumonic Pleural Effusion Pregnancy breastfeed Critically illness Systemic anticoagulant treatment Coagulation Disorder Bronchopleural fistula Active bleed Recent punction noncompressive artery Stroke last 6 month Major intervention major traumatism last 6 week Hypersensibility urokinase alteplase Severe Liver kidney failure Inclusion another interventional study last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>